The data is incremental and consistent with previously announced December 2025 topline results. No new regulatory catalyst or financial update, monitor for FDA meeting outcomes and Phase 3 initiation plans as the next value drivers.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $114.24entry
- T+1 · 6mo ago −8.04%α −7.98% · $105.05
- T+5 · 6mo ago −0.22%α −1.18% · $113.99
- T+20 · 5mo ago +1.99%α −0.13% · $116.51
- T+60 · 3mo ago +35.07%α +30.55% · $154.30
Price Chart
How similar events traded
Executive Summary
Palvella Therapeutics announced new Phase 2 TOIVA trial data for QTORIN rapamycin in cutaneous venous malformations, presented at the SID annual meeting. The data showed 100% of patients with baseline bleeding achieved statistically significant improvement on the cVM-IGA Bleeding scale at Week 12 (+2.5 points, p=0.003). This is a clinical-stage biotech update with no financial figures or regulatory milestones, the filing is a routine data readout disclosure.
Key Facts
- Phase 2 TOIVA trial data presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
- 100% of patients with bleeding at baseline (n=4) showed statistically significant improvement on cVM-IGA Bleeding at Week 12 (+2.5 point improvement; p=0.003)
- 100% of patients with bleeding at baseline reported being satisfied or very satisfied with QTORIN rapamycin on the Treatment Satisfaction Questionnaire for Medication at Week 12
- QTORIN rapamycin has potential to become first FDA-approved therapy for an estimated >75,000 individuals with cutaneous venous malformations in the U.S.
- TOIVA is a single-arm, open-label, baseline-controlled Phase 2 trial with 12-week efficacy evaluation and 12-week extension period
Financial Impact
No financial figures disclosed in the filing. Clinical-stage company with no approved products or reported revenue.
Risk Factors
- Phase 2 data from a single-arm, open-label trial with only 4 patients evaluable for the bleeding endpoint, limited statistical power
- QTORIN rapamycin is investigational and not yet FDA-approved for any indication
- Clinical-stage biotech with no approved products or revenue, dependent on future capital raises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-225317 |
| Document: pvla-ex99_1.htm | 0001193125-26-225317 |
| Document: 0001193125-26-225317-index-headers.html | 0001193125-26-225317 |
| Document: 0001193125-26-225317-index.html | 0001193125-26-225317 |
| Document: 0001193125-26-225317.txt | 0001193125-26-225317 |
Track record
36 reports on PVLA
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers